乳癌治療治療薬の世界市場

◆英語タイトル:Frontier Pharma: Breast Cancer - First-in-Class Innovation Underlies Immunotherapeutic Potential and Pipeline Diversification for Late-Stage Breast Cancer
◆商品コード:DATA809017
◆発行会社(リサーチ会社):GBI Research
◆発行日:2018年7月
◆ページ数:122
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD6,995 ⇒換算¥727,480見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD13,990 ⇒換算¥1,454,960見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGBI Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
GBI Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Frontier Pharma: Breast Cancer – First-in-Class Innovation Underlies Immunotherapeutic Potential and Pipeline Diversification for Late-Stage Breast Cancer
Summary

Breast cancer remains a major global healthcare concern despite exceptional levels of public awareness about the disease. A lack of clear causative environmental factors and hereditary dispositioning have resulted in the incidence of breast cancer continuing to rise, a trend which is expected to continue into the immediate future.

In the UK, breast cancer is the leading type of cancer in women, with there being over 54,900 cases diagnosed each year. Although early-stage cancer is relatively treatable and has good 5- and 10-year disease-free survival rates, 10% of cancers are diagnosed late. Additionally, there are no treatments for metastatic breast cancer, which ultimately results in death.

As a whole, this presents a huge unmet clinical need in the breast cancer treatment algorithm. The treatment algorithm for breast cancer focuses on two main themes: standard chemotherapy and drugs that target hormones, namely estrogen and progesterone. However, chemotherapy and hormone drugs only make up a small percentage of the drug pipeline and an even smaller percentage of first-in-class products.

New trends in oncology are present in the breast cancer pipeline, in particular the focus on extracellular matrix degradation and improving the immune response to tumors. This report focuses on the epidemiology, pathophysiology and existing treatment options for breast cancer before giving detailed insight into promising pipeline targets and deal activity in the breast cancer market.

Scope

- Unmet need is extremely high in late-stage breast cancer.
- What are the most important etiological risk factors and pathophysiological processes implicated in breast cancer?
- What is the current treatment algorithm?
- How effective are current therapies for these indications, and how does this impact prognosis?
- The breast cancer pipeline is large and contains a very high proportion of first-in-class product innovation.
- Which molecule types and molecular targets are most prominent across the breast cancer pipeline?
- What are the relationships between established and up-coming molecular targets in breast cancer?
- Which first-in-class targets are most promising?
- How does first-in-class target diversity differ by stage of development and molecular target class?
- The deals landscape is active and dominated by very high and very low deal values.
- Which indications attract the highest deal values?
- How has deal activity fluctuated over the past decade?
- Which first-in-class pipeline products have no prior involvement in licensing or co-development deals?

Reasons to buy

- Appreciate the current clinical and commercial landscapes by considering disease symptoms, pathogenesis, etiology, co-morbidities and complications, epidemiology, diagnosis, prognosis and treatment options.
- Identify leading products and key unmet needs within the market.
- Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.
- Assess the therapeutic potential of first-in-class targets. Using proprietary matrix assessments, first-in-class targets in the pipeline have been assessed and ranked according to clinical potential.
- Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals, which may represent potential investment opportunities.

【レポートの目次】

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 4
2 Executive Summary 6
2.1 Exceptionally Large and Innovative Pipeline 6
2.2 Alignment of First-in-Class Molecular Target with Disease Causation 6
2.3 Highly Active Deals Landscape with Numerous Investment Opportunities 6
3 The Case for Innovation 7
3.1 Growing Opportunities for Biologic Products 7
3.2 Diversification of Molecular Targets 8
3.3 Innovative First-in-Class Product Developments Remain Attractive 8
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Innovation 9
3.5 Sustained Innovation in Breast Cancer 9
3.6 Report Guidance 9
4 Clinical and Commercial Landscape 11
4.1 Overview of Breast Cancer 11
4.2 Symptoms 11
4.3 Diagnosis 11
4.4 Etiology 12
4.4.1 Age and Gender 12
4.4.2 Genetics 12
4.4.3 Environmental 13
4.5 Pathophysiology 13
4.5.1 Tumor Initiation and Aberrant Cell Proliferation and Survival 13
4.5.2 Tumor Metabolic Shift 14
4.5.3 Tumor Progression, Micro-environment Alteration and Angiogenesis 15
4.5.4 Cancer Stem Cells 16
4.6 Epidemiology 16
4.7 Complications 17
4.8 Prognosis and Disease Staging 18
4.8.1 Classification 19
4.9 Introduction to Breast Cancer Treatments 20
4.9.1 Treatment Algorithm 20
4.9.2 Treatment Options for Breast Cancer 22
4.10 Overview of Marketed Products in Breast Cancer 26
4.11 Current Unmet Needs in the Breast Cancer Market 27
5 Assessment of Pipeline Product Innovation 29
5.1 Overview 29
5.2 Breast Cancer Pipeline by Phase of Development and Molecule Type 29
5.3 Pipeline by Molecular Target 30
5.4 Comparative Distribution of Programs between the Market and Pipeline by Molecular Target Class 32
5.5 Comparative Distribution of First-in-Class and Non-First-in-Class Pipeline Programs by Molecular Target Class 32
5.5.1 Percentage Distribution of First-in-Class and Non-First-in-Class Pipeline Programs 35
5.6 Ratio of First-In-Class Programs to First-in-Class Molecular Targets within the Pipeline 36
5.7 List of All First-in-Class Pipeline Programs 38
6 Signaling Network, Disease Causation and Innovation Alignment 62
6.1 Complexity of Signaling Networks in Breast Cancer 62
6.2 Signaling Pathways, Disease-Causing Mutations and First-in-Class Molecular Target Integration 62
6.3 First-in-Class Molecular Target Matrix Assessment 63
7 First-in-Class Target Evaluation 70
7.1 Pipeline Programs Targeting PI3K Catalytic Subunit Alpha Isoform (PI3KCA) 70
7.2 Pipeline Programs Targeting GTPase KRAS (K-ras) 71
7.3 Pipeline Programs Targeting Cluster of Differentiation 47 (CD47) 72
7.4 Pipeline Programs Targeting CD278 (ICOS gene product) 74
7.5 Pipeline Programs Targeting Stimulator of Interferon Genes (TMEM173 gene product) 74
7.6 Pipeline Programs Targeting Receptor Tyrosine Protein Kinase ERBB 3 (HER3) 76
7.7 Pipeline Programs Targeting Neuregulin-1 (NRG1) 79
7.8 Pipeline Programs Targeting Calcium Release-Activated Calcium Channel Protein 1 (ORAI1) 80
7.9 Conclusion 81
8 Strategic Consolidations 83
8.1 Industry-Wide First-in-Class Deals 83
8.2 Breast Cancer Deals Landscape 84
8.3 Licensing Deals 85
8.3.1 Deals by Region, Value and Year 85
8.3.2 Deals by Stage of Development and Value 86
8.3.3 Deals by Molecule Type and Molecular Target 87
8.3.4 List of Deals with Disclosed Deal Values 88
8.4 Co-development Deals 92
8.4.1 Deals by Region, Value and Year 92
8.4.2 Deals by Stage of Development and Value 93
8.4.3 Deals by Molecule Type and Molecular Target 94
8.4.4 List of Deals with Disclosed Deal Values 95
8.5 First-In-Class Programs with and without Prior Licensing or Co-development Deal Involvement 96
9 Appendix 105
9.1 Abbreviations 105
9.2 References 106
9.3 Methodology 120
9.3.1 Data integrity 120
9.3.2 Innovative and Meaningful Analytical Techniques and Frameworks 120
9.3.3 Evidence Based Analysis and Insight 120
9.4 Secondary Research 120
9.4.1 Market Analysis 121
9.4.2 Pipeline Analysis 121
9.4.3 Licensing and Co-development Deals 121
9.5 Contact Us 122
9.6 Disclaimer 122

1.1 List of Tables
Table 1: Breast Cancer, Global, Tumor, Regional Lymph Node and Metastasis Staging, 2010-2013 18
Table 2: Breast Cancer, Global, US, Disease Stage at Diagnosis and Five-year Relative Survival (%), 2013 18
Table 3: Breast Cancer, Global, Breast Cancer Histopathological and Molecular Classification, 2018 19
Table 4: Breast Cancer, Global, Key Features of Phosphoinositide 3-kinase Catalytic Subunit Alpha Isoform (PI3K), 2018 70
Table 5: Breast Cancer, Global, Pipeline Programs Targeting Phosphoinositide 3-kinase Catalytic Subunit Alpha Isoform (PI3K), 2018 71
Table 6: Breast Cancer, Global, Key Features of GTPase KRAS (K-ras), 2018 72
Table 7: Breast Cancer, Global, Pipeline Programs Targeting GTPase KRAS (K-ras), 2018 72
Table 8: Breast Cancer, Global, Key Features of Cluster of Differentiation 47 (CD47), 2018 73
Table 9: Breast Cancer, Global, Pipeline Programs Targeting Cluster of Differentiation 47 (CD47), 2018 73
Table 10: Breast Cancer, Global, Key Features of Cluster of Differentiation 278 (CD278), 2018 74
Table 11: Breast Cancer, Global, Pipeline Programs Targeting Cluster of Differentiation 278 (CD278), 2018 74
Table 12: Breast Cancer, Global, Key Features of Stimulator of Interferon Genes (STING), 2018 75
Table 13: Breast Cancer, Global, Pipeline Programs Targeting Stimulator of Interferon Genes (STING), 2018 76
Table 14: Breast Cancer, Global, Key Features of Tyrosine Protein Kinase ERBB3 (HER3), 2018 77
Table 15: Breast Cancer, Global, Pipeline Programs Targeting Tyrosine Protein Kinase ERBB3 (HER3), 2018 78
Table 16: Breast Cancer, Global, Key Features of Neuregulin-1 (NRG-1), 2018 80
Table 17: Breast Cancer, Global, Pipeline Programs Targeting Neuregulin-1 (NRG-1), 2018 80
Table 18: Breast Cancer, Global, Key Features of Calcium Release Activated Calcium Channel Protein 1 (ORAI1), 2018 81
Table 19: Breast Cancer, Global, Pipeline Programs Targeting Calcium Release Activated Calcium Channel Protein 1 (ORAI1), 2018 81

1.2 List of Figures
Figure 1: Breast Cancer, Global, Innovation Trends in Product Approvals Across the Pharmaceutical Market, 1987-2014 7
Figure 2: Breast Cancer, Global, Post-Marketing-Approval Sales Performance of First-in-Class Products Across the Pharmaceutical Industry ($m), 2006-2013 8
Figure 3: Breast Cancer, Global, Treatment Algorithm for Cancer Diagnosed at Stages I to III, 2018 21
Figure 4: Breast Cancer, Global, Treatment Algorithm for Cancer Diagnosed at Stage IV, 2018 22
Figure 5: Breast Cancer, Global, Market by Molecule Type and Molecular Target, 2018 27
Figure 6: Breast Cancer, Global, Pipeline Size by Therapy Area, 2018 29
Figure 7: Breast Cancer, Global, Pipeline by Stage of Development and Molecule Type, 2018 30
Figure 8: Breast Cancer, Global, Pipeline by Molecular Target and Breakdown of Growth Factor Antagonist Molecular Target Class, 2018 31
Figure 9: Breast cancer, Global, Distribution of Pipeline and Marketed Products by Molecular Target Class, 2018 32
Figure 10: Breast Cancer, Global, Distribution of Pipeline Products by First-in-Class Status and Molecular Target Class, 2018 34
Figure 11: Breast Cancer, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Products by Stage of Development and Molecular Target Class, 2018 36
Figure 12: Breast Cancer, Global, Ratio of First-in-Class Products to First-in-Class Targets by Stage of Development and Molecular Target Class, 2018 37
Figure 37: Breast Cancer, Global, First-in-Class Molecular Target Matrix Assessment for Breast Cancer, 2018 (part 1) 64
Figure 44: Breast Cancer, Global, Industry-Wide Licensing Deals by First-in-Class Status and Stage of Development, 2006-2015 83
Figure 45: Breast Cancer, Global, Industry-Wide Licensing Deals by First-in-Class Status, Deal Value, Upfront Payment Value and Stage of Development, 2006-2014 84
Figure 46: Breast Cancer, Global, Licensing Deals by Region, Value and Year, 2006-2018 86
Figure 47: Breast Cancer, Global, Licensing Deals by Deal Value, Upfront Payment Value and Stage of Development, 2006-2018 87
Figure 48: Breast Cancer, Global, Number and Aggregate Deal Value of Licensing Deals by Molecule Type and Molecular Target Class, 2006-2018 88
Figure 52: Breast Cancer, Global, Co-development Deals by Region, Value and Year, 2006-2018 92
Figure 53: Breast Cancer, Global, Number and Aggregate Deal Value of Co-development Deals by Stage of Development and Year, 2006-2018 93
Figure 54: Breast Cancer, Global, Number and Aggregate Deal Value of Co-development Deals by Molecule Type and Molecular Target Class, 2006-2018 94
Figure 55: Breast Cancer, Global, Number and Aggregate Deal Value of Co-development Deals by Molecule Type and Molecular Target Class, 2006-2018 95

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[乳癌治療治療薬の世界市場]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆